DDInter1592 DDInter899
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A4
Rifapentine {u} (Compound) upregulates {v} (Gene) DDIT4
Rifapentine {u} (Compound) is included by {v} (Pharmacologic Class) Rifamycins
Rifapentine (Compound) resembles Rifabutin (Compound)
Rifapentine (Compound) resembles Rifaximin (Compound)
Rifapentine (Compound) binds CYP3A4 (Gene)
Rifapentine (Compound) upregulates DDIT4 (Gene)
Rifapentine (Compound) is included by Rifamycins (Pharmacologic Class)